Searches for sermorelin before and after usually want one thing: real numbers on what changes, and when. The honest answer sits in a small set of human studies, not a gallery of transformation photos, and runs in weeks and months, not days.
The Compound Universe take: Sermorelin before and after data show a fast IGF-1 climb (about two weeks) but only a modest 1.26 kg lean-mass shift over 16 weeks in men, so the visible “after” most sellers imply is really a slow hormone signal, not a body transformation. Its most well-documented result is height velocity in kids with growth hormone deficiency, the population its original approval targeted, not adult physique change.
See how this timeline compares to other anti-aging-adjacent peptides.
New to this peptide? See the sermorelin mechanism and evidence profile for the full research background before comparing any timeline.
What “sermorelin before and after” is actually asking
Sermorelin is not growth hormone. It is a 29-amino-acid fragment of human growth-hormone-releasing hormone, GHRH(1-29), one step upstream of GH itself.
Sermorelin binds the GHRH receptor on pituitary somatotroph cells, prompting those cells to release the body’s own growth hormone in a pulse rather than a constant flow [1]. The pituitary still answers to somatostatin, the hormone that reins GH back in, so sermorelin’s effect stays inside the body’s normal feedback loop, unlike direct GH injection [1][4]. That is why “before and after” claims here describe gradual, feedback-limited change, not a sudden spike.
| Attribute | Detail |
|---|---|
| Class | 29-amino-acid GHRH(1-29) analog (growth hormone secretagogue) |
| Mechanism | Binds the GHRH receptor on pituitary somatotrophs; triggers pulsatile GH release |
| Most-studied changes | IGF-1 rise, modest lean-mass gain in men, skin thickness, pediatric height velocity |
| Evidence tier | Small human RCT (1997) + retrospective case series + historic pediatric trials |
| Regulatory status (US, July 2026) | Previously FDA-approved as Geref (NDA 020443, 1997); discontinued 2008; today available only via compounding pharmacies, not as an approved marketed drug |
How sermorelin is thought to change the body over time
Two to four weeks: the IGF-1 response
RCT evidence: nightly sermorelin in older adults
The clearest early marker in the literature is IGF-1, the downstream hormone GH triggers the liver to produce. In a placebo-controlled trial of 19 adults aged 55 to 71, nightly sermorelin raised serum IGF-1 within about two weeks in both sexes, alongside a significant rise in nocturnal GH output [1]. Human (small RCT): the most direct controlled evidence for an early “after” marker.
Retrospective evidence: combination therapy in hypogonadal men
A retrospective chart review of 14 hypogonadal men on combination therapy (sermorelin plus GHRP-6 and GHRP-2, three injections daily for a mean of 134 days) found IGF-1 rising from 159.5 ng/mL at baseline to 239.0 ng/mL on treatment (p<.0001) [2]. Human (retrospective, combination therapy): the number is real, but sermorelin was not isolated from the other two peptides.
Compound Universe take: That 159.5-to-239.0 ng/mL jump gets cited as proof sermorelin “works,” but it came from three peptides stacked together for four-plus months, not sermorelin alone, so it answers a different question than what one compound does on its own clock.
Three to five months: body composition and skin thickness
In that same 1997 trial, over 16 weeks men gained an average of 1.26 kg of lean mass versus placebo (p<0.05) and showed improved insulin sensitivity; women showed no significant lean-mass change [1]. Both sexes showed a significant rise in skin thickness, a marker of dermal collagen content [1]. The only adverse event was transient hyperlipidemia that resolved by study's end [1]. Human (small RCT): real, measured, but modest, not a body-recomposition transformation.
Sustained change in pediatric growth hormone deficiency
Sermorelin’s most established before-and-after outcome is not an adult anti-aging effect. It is height velocity in children with growth hormone deficiency, the population the original 1997 FDA approval targeted [3]. Review data describe sustained height-velocity gains over 12 months, with limited longer-run data in a small number of children suggesting the effect held through 36 months [3]. Human (pediatric clinical trials): the strongest evidence tier sermorelin carries.
Compound Universe take: Even sermorelin’s best-documented before-and-after story is a 12-month height chart in a growing child, with only limited data past that – a different picture than the “adult before and after” intent behind this search term.
| Measured change | Evidence maturity | Study type | Regulatory status (US) |
|---|---|---|---|
| IGF-1 rise (2-4 weeks) | Human, small samples | RCT (n=19) [1] + retrospective (n=14) [2] | Compounded only; not FDA-approved as marketed drug |
| Lean-mass gain, men (~1.26 kg / 16 wk) | Human, single RCT | Placebo-controlled, small [1] | Same as above |
| Pediatric height velocity | Human, historic trials | Trials supporting 1997 approval [3] | Previously FDA-approved (discontinued 2008) |
| Adult “anti-aging” body composition | Opinion / limited data | Editorial commentary [4] + secretagogue reviews [5] | Off-label, unapproved use |
What the before-and-after evidence does not show
A 2006 editorial asked whether sermorelin is “a better approach” to adult-onset growth hormone insufficiency than direct GH replacement [4]. This is a perspective piece, not new trial data.
The adult evidence base is narrow: one small 1997 RCT in older adults, plus a 14-person retrospective review that cannot isolate sermorelin’s individual contribution [1][2]. No modern controlled trial has tested sermorelin alone in healthy, non-deficient adults chasing body-composition change, and no validated “before and after photo” outcome exists in the literature.
Broader reviews of GH secretagogues in hypogonadal men frame this honestly: these compounds are studied as a possible adjunct to testosterone therapy, not a replacement, and testosterone remains the better-evidenced option [5].
Weighing this against the other leading GH secretagogue.
Read this before comparing timelines: Sermorelin was FDA-approved as Geref for pediatric growth hormone deficiency from 1997 to 2008; the manufacturer discontinued it for commercial reasons, and the FDA formally determined it was not withdrawn for safety or effectiveness concerns [6]. As of July 2026, sermorelin is available only through licensed compounding pharmacies as a prescription product; no compounded version carries FDA approval as a finished drug. This article summarizes published research. It is not medical advice, a dosing guide, or an endorsement of use, and legal/regulatory status can change.
Key takeaways
- IGF-1 is the clearest marker: it rose within about two weeks in the 1997 RCT and climbed from roughly 160 to 239 ng/mL over four months in a separate retrospective series [1][2].
- Lean-mass change in that RCT was real but modest, about 1.26 kg in men over 16 weeks, with no significant change in women [1].
- Pediatric height-velocity gains are sermorelin’s most established outcome, anchoring its original 1997 FDA approval [3].
- Sermorelin has not been FDA-approved as a marketed drug since 2008; today it is prescription-only and compounded [6].
- Most adult “before and after” claims online outrun the primary literature: one small controlled trial plus a handful of retrospective or combination-therapy reports [1][2][5].
Frequently asked questions
How long does it take to see sermorelin before-and-after results?
IGF-1 began rising within about two weeks in the controlled trial, while lean-mass and skin-thickness changes in men took the full 16 weeks to reach significance [1].
What changes first after starting sermorelin?
The earliest documented change is a rise in IGF-1 and nocturnal GH output, before any body-composition difference is measurable [1][2].
Is sermorelin still FDA-approved?
No. Geref, the branded version, was FDA-approved in 1997 for pediatric growth hormone deficiency and voluntarily discontinued in 2008 for commercial reasons; the FDA confirmed the withdrawal was not safety-related [6]. As of July 2026 it exists only as a compounded, prescription-only product.
Does sermorelin cause dramatic body-transformation results?
No. The one controlled adult trial recorded a modest lean-mass gain in men (about 1.26 kg over 16 weeks) and no significant change in women [1].
How is sermorelin different from taking growth hormone directly?
Sermorelin prompts the pituitary to release its own growth hormone in pulses and stays subject to the somatostatin feedback loop, while direct GH injection bypasses that feedback entirely [1][4].
Is sermorelin legal to buy in 2026?
It is a prescription compound dispensed through licensed 503A/503B compounding pharmacies in the US, not an OTC or FDA-approved finished product; status can vary, so verify current rules before relying on any claim.
| Timeframe | What’s measured | Evidence tier |
|---|---|---|
| 2-4 weeks | IGF-1 and nocturnal GH rise | Small RCT + retrospective series [1][2] |
| 3-5 months | Lean mass (+1.26 kg, men), skin thickness | Single small RCT [1] |
| 12-36 months | Height velocity, pediatric GHD | Historic trials behind 1997 approval [3] |
| Ongoing | Adult “anti-aging” body composition | Editorial opinion, not controlled data [4][5] |
Confirm the current legal and compounding-pharmacy status.
The sermorelin before-and-after picture connects several related threads: GHRH(1-29) signaling through pituitary somatotrophs, the IGF-1 response that follows, the somatostatin feedback loop that limits it, and the broader growth-hormone-secretagogue category that includes GHRP-6, GHRP-2, and ipamorelin as comparison compounds; Compound Universe tracks each of these against the primary literature and its current compounding-pharmacy status rather than marketing timelines.
Whatever timeline a seller promises, the real sermorelin before and after evidence is narrower and slower: an IGF-1 rise inside a month, a modest lean-mass change in men, and its strongest record in pediatric growth hormone deficiency, not adult transformation.
Compare next: are peptides legal | Compound Universe’s sermorelin vs ipamorelin comparison
References
- Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-9. PMID 9141536.
- Sigalos JT, Pastuszak AW, Allison A, et al. Growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels. Am J Mens Health. 2017. PMID 28830317.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. PMID 18031173.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-8. PMID 18046908.
- Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. PMID 32257855.
- US Federal Register. Determination that GEREF (Sermorelin Acetate) Injection was not withdrawn from sale for reasons of safety or effectiveness. Docket FDA-2012-P-1071, published March 4, 2013.